Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 13/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | DRD3 | P35462 | 6/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540825 | 0.92 | OPRK1 (0.50) | OPRK1OPRM1OPRD1HTR2CHTR6 | |
| SCHEMBL6541125 | 0.85 | SMN1; SMN2 (0.51) | OPRK1OPRM1OPRD1IDO1L3MBTL1 | |
| SCHEMBL6540146 | 0.82 | LPAR1 (0.52) | HTR2CHTR6L3MBTL1 | |
| SCHEMBL6540922 | 0.80 | L3MBTL1 (0.48) | OPRK1OPRM1OPRD1IDO1L3MBTL1 | |
| SCHEMBL6539946 | 0.78 | OPRK1 (0.51) | OPRK1OPRM1OPRD1HTR6DRD2 | |
| SCHEMBL15265085 | 0.77 | OPRK1 (0.54) | OPRK1OPRM1OPRD1DRD2DRD3 | |
| SCHEMBL7228409 | 0.76 | MEN1 (0.61) | L3MBTL1 | |
| SCHEMBL6539665 | 0.76 | LPAR1 (0.57) | L3MBTL1 | |
| SCHEMBL2219811 | 0.75 | IGF1R (0.60) | OPRK1DRD2DRD3L3MBTL1DRD1 | |
| SCHEMBL6541013 | 0.73 | CA12 (0.50) | OPRK1OPRM1OPRD1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | OPRK1 89/4885OPRM1 180/4885OPRD1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.